Weekly shot could help shed pounds in obesity trial
NCT ID NCT07648225
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 study tests whether a weekly injection called UBT251 can help overweight or obese adults lose weight. Participants receive either the drug or a placebo for 52 weeks. The main goal is to measure the percentage change in body weight, with additional checks on waist size, BMI, and blood pressure. The trial includes adults aged 18-75 with a BMI of 24 or higher who also have conditions like prediabetes, high blood pressure, or fatty liver.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
UBT251 injection
What this could lead to
If successful, this could offer a new weekly injection option for significant weight loss in people with obesity or overweight who have related health issues.
What could go wrong
This is a phase 3 trial, but results may not apply to everyone. Side effects are possible, and the drug may not work as well in real-world settings or for all participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
Beijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••